Location & dates EMBL Heidelberg, Germany 5 - 7 Feb 2020
Deadlines Registration closed Abstract submission closed

Programme

Got something to say? Tweet it! #EMBLProteome 

Day 1 - Wednesday 05 February 2020
TimeSpeaker
11:00-13:00 Arrival and Registration 
with light refreshments

11:45-12:45

Pre-conference workshop
13:00-13:30 Opening talk
The challenge of expanding the druggable proteome
Adrian Carter, Boehringer Ingelheim, Germany
13:30-15:00

Session 1: Illuminating the challenge and highlighting the opportunity for creating new medicines
Chair: Adrian Carter

13:30-14:00

Illuminating the Druggable Genome with Informatics, Data Science and Machine Learning 
Tudor Oprea - University of New Mexico, USA

14:00-14:30

Functionalization of the human protein-coding genome to discover medicines for neurodegenerative disease
Heiko Runz - Biogen, USA

14:30-15:00

Chemical probes and the chemical biology of cancer
Paul Workman - CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK

15:00-15:30

Coffee break

15:30-17:45

Session 2: Illuminating the most promising proteins by virtue of druggability, human genetics and bioinformatics
Chair: Patrick Aloy

15:30-16:00

Harnessing genetic interactions to discover new cancer targets and combinations
Eytan Ruppin - National Cancer Institute, USA

16:00-16:15

Proteome-wide identification of new druggable targets for antibiotics
Stephan Hacker - Technical University of Munich, Germany

16:15-16:45

Kristin Brown - GlaxoSmithKline, UK

16:45-17:15

Epigenetic variation across individuals to understand disease mechanisms
Judith Zaugg - EMBL Heidelberg, Germany

17:15-17:45

Extending the small molecule similarity principle to all levels of biology 
Patrick Aloy - IRB Barcelona, Spain

17:45-18:35

Poster Session 1 - odd numbers
with beer and snacks, ATC Helix A

18:40-19:30

Poster Session 2 - even numbers
with beer and snacks, ATC Helix A

19:30-20:45

Dinner
EMBL Canteen

20:45-22:00 After Dinner Drinks
ATC Rooftop Lounge
20:00, 21:00, 22:00  Bus departure
Day 2 - Thursday 06 February 2020
TimeSpeaker
09:00-12:30

Session 3: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 1
Chair: Gerard Drewes

09:00-09:30

Shaping biology by modulating access to chemical matter
Giulio Superti-Furga - Center for Molecular Medicine, Austria

09:30-09:45

The target landscape of 1,200 kinase inhibitors
Maria Reinecke - Technical University of Munich, Germany

09:45-10:00

Covalent inhibitors for 'undruggable' targets
Nir London - The Weizman Institute of Science, Israel

10:00-10:30

Stefan Knapp - Goethe University Frankfurt, Germany

10:30-11:00

Coffee break

11:00-11:30

Exploring the druggable proteome by image-based phenotyping in cell lines and patient derived organoids 
Michael Boutros - German Cancer Research Centre, Germany

11:30-12:00

Mechanisms of intracellular DNA sensing through the cGAS-STING pathway
Andrea Ablasser - EPFL, Switzerland

12:00-12:15

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Georg Petzold - Friedrich Miescher Institute for Biomedical Research, Switzerland

12:15-12:30

Stabilization of protein-protein interactions
Pim de Vink - Eindhoven University of Technology, The Netherlands

12:30-14:00

Meet the speakers and lunch

14:00-16:00

Session 4: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 2
Chair: Anke Müller-Fahrnow

14:00-14:30

Tetrahydrobiopterin homeostasis
Kai Johnsson - Max Planck Institute for Medical Research, Germany 

14:30-15:00

Chemical physiology of natural products and antibody conjugates
Gonçalo Bernardes - University of Cambridge, UK and iMM Lisboa, Portugal

15:00-15:30

Within our control? Leveraging precision electrophile signaling toward drug discovery
Yimon Aye - EPFL, Switzerland

15:30-16:00

Understanding cellular phenotypes; from screens to probes towards clinical candidates
Marcus Bauser - Bayer AG, Germany

16:00-16:30

Coffee break

16:30-19:00 Session 5: Interrogating the druggable proteome with phenotypic screens
Chair: Herbert Waldmann 
16:30-16:45 Towards improved biophysical models of protein folding to identify disease-causing mutations and rescue by small molecules
Amelie Stein - University of Copenhagen, Denmark
16:45-17:00 Using metabolic fingerprints to rationally design combination therapies
Mattia Zampieri - ETH Zürich, Switzerland
17:00-17:30 Pseudo Natural Products 
Herbert Waldmann - Max Planck Institute of Molecular Physiology, Germany
17:30-18:00

A systems approach to functional precision medicine by deep learning and multi-OMICs
Berend Snijder - ETH Zürich, Switzerland

18:00-18:30 Advances in phenotypic and pathway profiling: Elucidating novel target biology and drug mechanism-of-action under appropriate biological context 
Neil Carragher - The University of Edinburgh, UK
18:30-19:00

Lipid metabolism connecting the dots
Anne-Claude Gavin - University of Geneva, Switzerland

19:00-20:30 Conference Dinner
EMBL Canteen
20:30-23:00 After Dinner Drinks, live music
ATC Rooftop Lounge
20:00, 21:30, 23:00 Bus departure
Day 3 - Friday 07 February 2020
TimeSpeaker
09:00-10:45 Session 6: New engineering approaches for expanding the druggable proteome
Chair: Stefan Knapp
09:00-09:30

Mapping genetic networks using functional and chemical genomics
Brenda Andrews - University of Toronto, Canada

09:30-10:00

Biophysical screening of combinatorial libraries to target protein-protein interactions with covalent agents
Maurizio Pellecchia - University of California, Riverside, USA

10:00-10:15

NanoBRET cellular target engagement assays are versatile in enabling drug screening for various proteins – the SGC experience
Benedict Berger - Structural Genomics Consortium, Goethe University Frankfurt, Germany

10:15-10:45

Chemical Biology at the Interface of Discovery to Deliver Novel to Targets to the Drug Discovery Pipeline
Christine Donahue - GlaxoSmithKline, USA

10:45-11:15

Coffee break

11:15-13:15

Session 7: New engineering approaches for breaking the druggability barrier
Chair: Anne-Claude Gavin

11:15-11:45

Targeting the active site of E3 ligases with chemical tools
Katrin Rittinger - The Francis Crick Institute, UK

11:45-12:15

Structure based PROTAC design to expand the druggable Proteome
Alessio Ciulli - University of Dundee, UK

12:15-12:45

Chemical probes in target discovery
Paul Brennan - University of Oxford, UK

12:45-13:15

Identification of microbiome-encoded enzymes involved in drug metabolism
Michael Zimmermann - EMBL Heidelberg, Germany

13:15-13:30 Closing remarks and Poster Prize
13:30-14:00

End of conference
Packed lunch and departure

14:00

Bus departure all stops downtown

14:10

Bus to Frankfurt Intl. Airport